Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department

As of March 30(th), 2020 there were 161,807 total cases and 2,953 total deaths of SARS-CoV-2 in the United States, with the number of cases expected to rise. Other than supportive care, there are no SARS-CoV-2 specific treatments available for patients discharged from the emergency department (ED) o...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Cortlyn, Noble, Jeanne, Coralic, Zlatan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Department of Emergency Medicine, University of California, Irvine School of Medicine 2020
Materias:
Endemic Infections
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234712/
https://www.ncbi.nlm.nih.gov/pubmed/32302280
http://dx.doi.org/10.5811/westjem.2020.3.47328
Descripción
Sumario:As of March 30(th), 2020 there were 161,807 total cases and 2,953 total deaths of SARS-CoV-2 in the United States, with the number of cases expected to rise. Other than supportive care, there are no SARS-CoV-2 specific treatments available for patients discharged from the emergency department (ED) or those admitted to the hospital. In addition, there are no vaccines available to protect our at-risk healthcare workers. The National Institutes of Health is conducting a Phase 1 clinical trial to evaluate for a potential vaccine and the recipients have started to receive the investigational vaccine.2 We present a brief overview of the potential prophylactic and treatment agents under investigation, some which could be initiated in the ED if proven effective.

Ejemplares similares